Dartmouth’s Graduate Program in Quantitative Biomedical Sciences (QBS) is offering a new master’s degree with a concentration in health data science beginning in fall 2018.
The 92 members of the Geisel School of Medicine Class of 2021 ended their first full week of classes on a high note as they donned the symbol of their new profession.
A team of Geisel researchers will receive funding from the Patient-Centered Outcomes Research Institute (PCORI) to design new methods for comparing the effectiveness of alternative therapies that can lead to improvements in practice and better outcomes for patients.
Geisel researchers take a close look at New Hampshire’s complex opioid epidemic, and one city’s novel response.
Project 439 seeks to stem the rising tide of opioid overdose deaths in New Hampshire while helping those struggling with substance abuse protect their health.
Learning about the challenges medically underserved populations face, or have faced, is essential to providing good care. Created by students from Geisel School of Medicine, Beyond the Books gives voice to these community members and teaches future physicians the value of listening.
Dartmouth ranks highly in a new measure of the impact of academic research on global innovation, according to the Nature Index 2017 Innovation supplement. The index examines how often research articles from top science journals are cited in third-party patents around the world.
Michael Sporn, MD, emeritus professor of pharmacology and toxicology, and medicine, is featured in Nature Index 2017 for his tremendous impact upon biomedical research and drug development.
Ninety-two members of the Geisel School of Medicine’s 221st class were enthusiastically welcomed to Hanover by the Dartmouth community as part of this year’s orientation for incoming medical students, which runs from August 7-11.
Morgan Gilman, a fourth-year graduate student in the McLellan Lab at Geisel, is helping lead efforts to understand how a particular type of protein allows deadly viruses—such as Ebola and RSV (respiratory syncytial virus)—to gain entry into host cells, and how antibodies can be developed to neutralize that process.